Advertisement

Peptides and neuronal function

  • Zygmunt L. Kruk
  • Christopher J. Pycock
Chapter
  • 58 Downloads

Abstract

In 1936, von Euler described the properties of an extract prepared from brain and gut which had the form of a white powder. This extract became known as substance P (SP), and it is discussed later in this chapter. The observation which was to prove to be of great significance was that the biological activity of substance P could be destroyed by trypsin, thus showing that substance P was a peptide. Some 30 years later, Harris showed that the release of hormones from the anterior pituitary was under the control of blood-borne factors. These blood-borne factors were released from the hypothalamus and carried to the anterior pituitary by a portal system. These factors were shown to be released from neurones in the hypothalamus, and furthermore, they were shown to be peptides. These observations led to the suggestion that peptides released from nerves could act as neurotransmitters.

Keywords

Dorsal Horn Vasoactive Intestinal Polypeptide Opioid Peptide Opiate Receptor Substantia Gelatinosa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further Reading

  1. Akil, H., Watson, S.J., Young, E., Lewis, M.E., Khachaturian, H. and Walker, M.J. (1984) Endogenous opioids: Biology and function. Ann. Rev. Neurosci., 7, 223–255.PubMedCrossRefGoogle Scholar
  2. Bloom, F.E. (1983) The endorphin. Ann. Rev. Pharmacol. Toxicol., 23, 151–170.CrossRefGoogle Scholar
  3. Campbell, G. (1987) Co-transmission. Ann. Rev. Pharmacol. Toxicol., 27, 51–70.CrossRefGoogle Scholar
  4. Haynes, L. (1988) Opioid receptors and signal transduction. TIPS, 9, No. 9.Google Scholar
  5. Hughes, J. (1975) Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res., 88, 295–308.PubMedCrossRefGoogle Scholar
  6. Iversen, L.L. (1983) Nonopioid neuropeptides in mammalin CNS. Ann. Rev. Pharmacol. Toxicol., 23, 1–27.CrossRefGoogle Scholar
  7. Lewis, D.A. and Bloom, F.E. (1987) Clinical perspectives on neuropeptide. Ann. Rev. Med, 38, 143–148.PubMedCrossRefGoogle Scholar
  8. Low, L-M, and Pfaff., D.W. (1988) Neuromodulatory actions of peptides. Ann. Rev. Pharmacol. Toxicol., 28, 163–188.CrossRefGoogle Scholar
  9. Maggie, J.E. (1988) Tachykinins. Ann. Rev. Neurosci., 11, 13–28.CrossRefGoogle Scholar
  10. Smith, A.P. and Lee, N.M. (1988) Pharmacology of dynorphin. Ann. Rev. Pharmacol. Toxicol., 28, 123–140.CrossRefGoogle Scholar

Copyright information

© Zygmunt L. Kruk and Christopher J. Pycock 1991

Authors and Affiliations

  • Zygmunt L. Kruk
    • 1
  • Christopher J. Pycock
    • 2
  1. 1.Department of Pharmacology Queen Mary and Westfield CollegeUniversity of LondonUK
  2. 2.Derriford HospitalPlymouthUK

Personalised recommendations